MedTrace Logo

A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy

NCT05303558 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 221

Last updated 2024-08-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the yearly conditional prostate-specific antigen (PSA) progression-free survival (PFS) probabilities in high-risk localized prostate cancer (HR LPC) participants following radical prostatectomy (RP) and perioperative hormonal therapies (that is, hormonal treatment before RP and / or after RP) over 5 years.

Conditions

  • High Risk Localized Prostate Cancer

Sponsors & Collaborators

  • Johnson & Johnson International (Singapore) Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson International (Singapore) Pte Ltd Clinical Trial · Johnson & Johnson International (Singapore) Pte. Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-24
Primary Completion
2023-06-07
Completion
2023-06-07

Countries

  • Japan
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05303558 on ClinicalTrials.gov